A pilot, open label, randomised clinical trial assessing the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine 200 mg once a day or emtricitabine 200 mg once a week or lamivudine 300 mg once a day.

Trial Profile

A pilot, open label, randomised clinical trial assessing the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine 200 mg once a day or emtricitabine 200 mg once a week or lamivudine 300 mg once a day.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs Emtricitabine (Primary) ; Lamivudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms Break
  • Most Recent Events

    • 07 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top